Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Liquidia's collaboration with Sandoz and development of new products like L606 show promise. Learn why LQDA stock is a Hold.

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

It is worth considering United Therapeutics (UTHR), which belongs to the Zacks Medical - Drugs industry. This drugmaker has an established record of topping earnings estimates, especially when ...

With a solid Zacks Rank and top-tier Value and VGM Style Scores, UTHR should be on investors' short list. Should You Invest in United Therapeutics Corporation (UTHR)? Before you invest in United ...

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life ...

Read Our Latest Stock Report on UTHR United Therapeutics Stock Performance NASDAQ:UTHR opened at $281.16 on Monday. The stock has a market capitalization of $12.63 billion, a P/E ratio of 12.35, a ...

In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against other most expensive stocks insiders are dumping in March. After being in the green ...